Welcome to our dedicated page for Fosun International news (Ticker: FOSUF), a resource for investors and traders seeking the latest updates and insights on Fosun International stock.
Fosun International Limited (FOSUF) generates a diverse stream of news that reflects its role as a global innovation-driven consumer group active in health, cultural tourism, consumption, financial services, and insurance. News coverage often focuses on how Fosun advances its innovation and globalization strategy across these areas.
Investors and observers following FOSUF can expect regular updates on topics such as interim and annual business results, strategic portfolio adjustments, and developments in core subsidiaries. In the health segment, news frequently highlights progress in innovative drugs, biopharmaceutical research, medical devices, and international regulatory milestones achieved by companies within the Fosun ecosystem.
In cultural tourism and consumption, Fosun-related news includes information on tourism projects, resort operations, and cultural initiatives that promote experiential consumption and international cultural exchange. In financial services and insurance, articles may cover credit ratings, international expansion of insurance operations, and asset servicing activities that align with the group’s asset-light strategy.
Fosun also appears regularly in ESG and sustainability news, including updates on corporate sustainability assessment scores, climate-related disclosures, and social responsibility programs such as rural healthcare support and contributions to global public health challenges. This news page aggregates such announcements, allowing readers to track how Fosun communicates its performance, strategic focus, and corporate citizenship over time.
By monitoring the FOSUF news feed on Stock Titan, users can review company-issued releases and related coverage that shed light on Fosun’s evolving business mix, geographic reach, and emphasis on innovation, globalization, and ESG practices.
Fosun International (HKEX: 00656) has been selected for the S&P Global's Sustainability Yearbook 2025 for the second consecutive year, highlighting its strong ESG performance. Out of 7,690 companies assessed across 62 industries, only 780 were selected, with just 10 from the industrial conglomerates sector.
The company achieved a CSA score of 70 in 2024, placing it in the top 5% among global peers and approximately 40 points above the industry average. Fosun has maintained an MSCI ESG rating of AA since 2021 and holds an HSI ESG rating of AA-.
Notable achievements include ranking in the top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) and recognition as an "Industry Mover". The company's "Rural Doctors Program" was also featured among the UN Global Compact's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" in November 2024.
Fosun International (HKEX: 00656) has signed a strategic cooperation agreement with Natixis Corporate & Investment Banking on January 16, 2025. The agreement strengthens their partnership that began in 2010 and was enhanced in 2014. Under the new agreement, Natixis CIB will provide Fosun with consulting and financial services in financing, transaction structuring, and risk hedging, leveraging its expertise in specialized fields and operations in Europe and the Americas.
The agreement was signed at the Bund Finance Center by Zhang Houlin, Senior Vice President and Co-CFO of Fosun International, and Liu Hong, Senior Country Manager, Greater China, Natixis CIB. Fosun, which operates in more than 35 countries, will benefit from Natixis CIB's network and resources to support its global development strategy. Natixis CIB, a subsidiary of French banking group Groupe BPCE, will utilize its high credit ratings and stable funding sources to support this partnership.
Fosun International (OTC:FOSUF) and Natixis CIB signed a strategic cooperation agreement on 16 January 2025 to deepen long‑term collaboration across advisory, financing, transaction structuring and risk hedging. Natixis CIB will leverage its international network, boutique M&A expertise, and stable funding to support Fosun and its subsidiaries' development and globalization. Fosun highlighted its global footprint in more than 35 countries and framed the deal as a continuation of a partnership that began in 2010 and strengthened in 2014 and 2018.
The agreement was signed at the Bund Finance Center with senior executives from both parties in attendance, and the press release discloses no financial terms or deal values.
Fosun International has achieved a significant milestone in S&P Global's 2024 Corporate Sustainability Assessment (CSA), scoring 70 points and ranking in the top 5% among global peers. This represents an improvement from their previous score of 68 points and top 6% ranking last year, significantly outperforming the industry average of 30 points.
The company received balanced scores across key dimensions: 72 in governance and economic, 68 in environmental, and 71 in social aspects. Notable achievements were recorded in Business Ethics, Environmental Policy, Energy, Climate Strategy, Risk Management, Human Capital Development, and Customer Relationship Management.
Fosun's commitment to ESG is further evidenced by its inclusion in S&P Global's Sustainability Yearbook 2024, its AA rating from MSCI ESG (unique among Greater China conglomerates), and its consistent presence in the FTSE4Good Index Series. The company recently launched its sustainable development strategy 'Create IMPACT' to drive innovation and global sustainability initiatives.
Fosun International has been awarded the prestigious 'Outstanding ESG Award' along with 'Best in ESG Practices' and 'Best in ESG Report' at the TVB ESG Awards ceremony held on December 13, 2024, in Hong Kong. The company, which operates in over 35 countries across healthcare, tourism, consumption, and insurance sectors, was recognized for its comprehensive ESG management system and sustainable development initiatives.
Notable achievements include their commitment to peak carbon emissions by 2028 and achieve carbon neutrality by 2050, the establishment of a Carbon Neutrality Committee, and significant healthcare innovations. Their pharmaceutical division has made breakthrough developments, including Yi Kai Da, the first CAR-T cell therapy approved in mainland China, and artesunate injections that have treated over 72 million severe malaria patients globally.
The company has implemented its 'Create IMPACT' sustainable development strategy, focusing on innovation, mindful operation, people-oriented approach, advanced governance, climate positivity, and transparency.
Atlantis Sanya hosts the 2024 China Mermaid Open Grand Final and Asian Cup on December 12th-13th, marking the first Asian Cup for mermaid sports. Over 70 top athletes from various Asian countries and regions compete at the Ambassador Lagoon, featuring 13,500 tonnes of seawater and an 11-metre-deep open-air setting.
The event, jointly hosted by multiple Chinese sports authorities and Fosun Tourism Group, represents a significant step toward internationalizing mermaid sports. The venue's 16.5-metre-wide, 10-metre-high acrylic viewing panel allows spectators to witness the underwater performances up close.
This marks the fourth consecutive year Atlantis Sanya has hosted the Mermaid Open, contributing to Hainan's development as a sports tourism destination and supporting China's national sports development strategies.
Fosun International (HKEX: 00656) has received five prestigious ESG awards from two global media outlets, highlighting its excellence in environmental, social, and governance practices. The company earned the ESG Leading Enterprise Award and ESG Leading Social Initiatives Award from Bloomberg Businessweek/Chinese Edition, alongside three awards from Global Banking and Finance Review.
The company's achievements include its 'Create IMPACT' sustainable development strategy, focusing on Innovation, Mindful Operation, People and Partner Orientation, Advanced Governance, Climate and Planet Positivity, and Transparency. Notable initiatives include the Rural Doctors Program, which has supported 25,000 rural doctors and benefited 3 million grassroots families, and their malaria treatment program, which has treated over 68 million patients globally.
Fosun International maintains an MSCI ESG Rating of AA, outperformed 94% of global peers in S&P Global's Corporate Sustainability Assessment, and operates responsibly in more than 35 countries and regions.
Fosun's Rural Doctors Program has been selected as one of the '20 Cases of Private Sector's Sustainable Development in China for 20 Years' by the United Nations Global Compact (UNGC). The program, launched in 2017, has reached 78 counties across 16 provinces in China, supporting 25,000 rural doctors and benefiting 3 million grassroots families. Fosun, which holds an MSCI ESG rating of 'AA', is the only conglomerate in Greater China to achieve this rating. The program has received multiple recognitions, including the 'National Advanced Collective in Poverty Alleviation' and 'China Charity Award'.
Fosun, China's largest private investor in Portugal, marks a decade of significant market presence since 2014. The company has built a robust ecosystem focused on insurance, banking, and healthcare through key investments: Fidelidade (Portugal's largest insurer), Luz Saúde (major healthcare group), and Millennium BCP (largest listed private bank). Fidelidade reported €2.808 billion in premiums (+5.9% YoY) and €104 million net income (+5.3% YoY) as of June 2024. The company has expanded to 13 countries, with international operations contributing over 30% of total premiums and 40% of profits. Digital transformation initiatives have shown success, with Fidelidade's app reaching 1.6 million users and BCP achieving €856 million in net profit in 2023.
Fosun International (HKEX: 00656) has been awarded The Asset ESG Corporate Awards 2024 - Platinum Award and Best Initiative in Social Responsibility at a ceremony in Singapore. The company's ESG strategy 'Create IMPACT' demonstrates its commitment to sustainable development.
Fosun has achieved significant milestones in ESG performance, being the only Greater China conglomerate rated AA by MSCI ESG Ratings and ranking in the top 1% of S&P Global's Sustainability Yearbook 2024 (China Edition). The company's innovations include breakthrough medical treatments, with Fosun Pharma's artesunate injection treating over 68 million malaria patients globally.
The company's 'WE Volunteer' program has engaged over 4,500 employees in public welfare activities, contributing 34,476 hours. Through Fosun Foundation, established in 2012, the company supports various social initiatives, including the Rural Doctors Program which has benefited 3 million grassroots families.